[go: up one dir, main page]

EP1766399A2 - Method of determining the presence and/or concentration of substances of interest in fluids - Google Patents

Method of determining the presence and/or concentration of substances of interest in fluids

Info

Publication number
EP1766399A2
EP1766399A2 EP05758809A EP05758809A EP1766399A2 EP 1766399 A2 EP1766399 A2 EP 1766399A2 EP 05758809 A EP05758809 A EP 05758809A EP 05758809 A EP05758809 A EP 05758809A EP 1766399 A2 EP1766399 A2 EP 1766399A2
Authority
EP
European Patent Office
Prior art keywords
interest
fluid
magnetic
substance
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05758809A
Other languages
German (de)
French (fr)
Inventor
Patricia Connolly
John Fuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IVMD UK Ltd
Original Assignee
IVMD UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IVMD UK Ltd filed Critical IVMD UK Ltd
Publication of EP1766399A2 publication Critical patent/EP1766399A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/18—Magnetic separation whereby the particles are suspended in a liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C2201/00—Details of magnetic or electrostatic separation
    • B03C2201/26—Details of magnetic or electrostatic separation for use in medical or biological applications

Definitions

  • the present invention relates to a method of determining the presence and/or concentration of substances of interest in fluids, and particularly although not exclusively the presence and/or concentration of substances of interest in biological fluids including measurement in a living body, such as a human body.
  • Probes have been used with tags that are radioactive, enzymatic, fluorescent, chemiluminescent and spectrophotmetric or colourimetric. End points of tagged probe measurement can therefore be revealed in a variety of systems include spectrophotometric, electrochemical, radioactive, colourimetric, amperometric or potentiometric.
  • Magnetic beads have been employed in multiple probe systems as a solid phase for the capture probe, providing a highly mobile bead system with high surface area for capture probe attachment [1]. Secondary probes or antibodies can then be added after molecular attachment to the capture probe and in the commonest application a magnetic field is then used to draw together the beads allowing a concentrate to form where the level of the tag can be measured.
  • a method of determining the presence and/or concentration of one or more substances of interest in a fluid comprising the steps of: attaching a magnetic particle to the or each substance of interest in the fluid and introducing the fluid into an inhomogeneous magnetic field having a field gradient and thereby determining the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest.
  • the fluid may be a liquid or gas, and may be a biological fluid such as a body fluid.
  • Substances of interest may include naturally occurring substances, substances that are the result of a chemical or biological reaction, such as drug by-products, and substances introduced into a fluid sample.
  • the substance may be a compound, especially a molecule and could be, for example a protein, hormone or DNA section.
  • magnetic particles particles of non-zero magnetic susceptibility.
  • the or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. A homogeneous or heterogeneous mixture of such particles may be employed.
  • the or each particle is formed from iron oxide. Particles of size in the range 5 nanometers to 100 micrometers may be used or in some embodiments particles of size in the range 5 nanometers to 50 micrometers may be used.
  • the or each particle may be attached to a substance of interest by means of a further substance, which shall be referred to as a bonding substance.
  • the or each particle may be coated with the bonding substance.
  • the bonding substance may be a protein, and in some embodiments it is an antibody or probe (ligand).
  • the or each magnetic particle may be coated with a material to facilitate adherence of a bonding substance to the particle.
  • a suitable coating material is polystyrene.
  • Magnetic particles may be attached to substances of interest prior to their introduction into a fluid, for example in the case of a drug injected into a human body.
  • magnetic particles coated with an appropriate bonding substance may be introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest, for example appropriately coated magnetic particles could be injected into a human body in order to identify the presence and/or concentration of specific drug by-products.
  • each magnetic particle may be arranged so that it can only become attached to a single unit of a substance of interest, for example a single molecule.
  • each particle may be provided with a single antibody or capture probe.
  • magnetic particles having different characteristics in a fluid By using magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances it is possible to determine the presence and/or concentration of more than one substance of interest in a given fluid. Any suitable characteristic of the magnetic particles may be altered, including size, shape and magnetic susceptibility. In some instances it is also possible to distinguish between magnetic particles with the same or similar characteristics attached to different substances of interest in a fluid, by virtue of differing characteristics of the substance of interest such as a mass.
  • the effect of the fluid to be analysed on the magnetic field is measured using a magnetic field sensor to determine magnetic particles in the fluid, and thereby the presence and/or concentration of substances of interest.
  • the magnetic field gradient is along a line in space.
  • magnetic particles in a fluid are introduced into the field gradient they will experience a force. The force experienced by each particle will depend upon its characteristics.
  • a fluid containing a number of magnetic particles which respond differently to a magnetic field is placed into an inhomogeneous magnetic field the different particles are subject to different forces and will thus tend to migrate to different regions of the field.
  • the magnetic particles present in the fluid will also influence the magnetic field in different ways.
  • particles of differing susceptibility are present in a fluid and the fluid is introduced into a magnetic field gradient. Particles of the same susceptibility will tend to migrate to the same position within the field gradient. The amount of particles present at any one point will affect the field strength at that point.
  • By measuring the strength of magnetic field in the region of the fluid along the field gradient it is possible to determine the presence and quantity of magnetic particles of differing susceptibility and thereby the concentration of particles of the same or similar susceptibility in the fluid sample.
  • Field gradients in the range 50 to 200 Tesla per metre may be typically employed and not excluding other field gradients.
  • Permanent magnets having shaped pole pieces may typically be used to provide a magnetic field gradient.
  • the particles can be detected in a classic
  • the particles are immobilised on a surface but are able to bond to a substance of interest though a specific bonding substance such as an antibody.
  • a sample is introduced to this surface which contains the substance of interest in an unknown quantity.
  • Competition for the binding site on the particle from the substance of interest in the sample will release the magnetic particles into solution in proportion to the concentration of the substance of interest in the sample.
  • the released particles experience a magnetic field gradient and hence are concentrated at a point determined by their susceptibility. This concentration varies the magnetic field and creates a point of high field density.
  • a magnetic sensor is placed at the point of highest field density to detect the particles thus greatly increasing the sensitivity of measurement.
  • the sensor may be a Hall Sensor, or any other sensitive magnetic measurement sensor.
  • the immobilised particles can be bound via any suitable bonding substance to substances of interest, multiple layers of different bonding substances can be used to create suitable sites for competition from substances of interest in the sample.
  • a displacement assay is used in the analytical system but measurement is made by a complex oscillating coil system, and an antibody capture site for particles. This cannot create the same level of field density, even with very high power inputs, and hence sensitivity is compromised. This results in more complex manufacture for both the sensing system and the disposable test element. Therefore it is not suitable for small, point of care machines.
  • prior art methods using magnetic particles utilise an immunoassay and adjacent magnets to move and measure spatial separation of magnetic particles
  • the present invention utilises the properties of a magnetic field gradient, knowledge of the effect of the particles on total field and a sensitive magnetic sensor to be able to determine the particle flow, both spatially and temporally, during the assay and to thereby determine the quantity of the substance of interest present in the sample being examined.
  • the ability to understand and utilise magnetic field gradients with magnetic particles in the present invention may also be employed to maximise the immunoassay efficiency and performance.
  • the present invention may utilise oscillating and other magnetic field arrangements to enhance particle - sample interactions and/or to manipulate flow rates during assays through manipulation of the particles.
  • a magnetic field may be introduced that will directly cause the magnetic particles to coagulate or cluster within a device slowing flow rates in the sample.
  • Higher amplification may be used to achieve greater sensitivity.
  • the method may include the application of an oscillating magnetic field to a solution of the fluid to be analysed and the magnetic particles to ensure mixing before introducing the fluid into the said inhomogeneous field with a field gradient.
  • a method of determining the presence and/or concentration of one or more substances of interest in a fluid comprising the steps of: introducing a fluid to be analysed is into a chamber containing magnetic particles bound with probes specific for the capture of the molecule of interest; mixing the magnetic particles with the fluid by the application of an oscillating magnetic field to the chamber to thereby determine the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest.
  • the fluid may be a liquid or gas, and may be a biological fluid such as a body fluid.
  • Substances of interest may include naturally occurring substances, substances that are the result of a chemical or biological reaction, such as drug by-products, and substances introduced into a fluid sample.
  • the substance may be a compound, especially a molecule and could be, for example a protein, hormone or DNA section.
  • magnetic particles is to be understood particles of non-zero magnetic susceptibility.
  • the or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. A homogeneous or heterogeneous mixture of such particles may be employed.
  • the or each particle is formed from iron oxide. Particles of size in the range 5 nanometers to 100 micrometers may be used or in some embodiments particles of size in the range 5 nanometers to 50
  • micrometers may be used.
  • the or each particle may be attached to a substance of interest by means of a further substance, which shall be referred to as a bonding substance.
  • the or each particle may be coated with the bonding substance.
  • the bonding substance may be a protein, and in some embodiments it is an antibody or probe (ligand).
  • the or each magnetic particle may be coated with a material to facilitate adherence of a bonding substance to the particle.
  • a suitable coating material is polystyrene.
  • Magnetic particles may be attached to substances of interest prior to their introduction into a fluid, for example in the case of a drug injected into a human body.
  • magnetic particles coated with an appropriate bonding substance may be introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest, for example appropriately coated magnetic particles could be injected into a human body in order to identify the presence and/or concentration of specific drug by-products.
  • the bonding substance it is possible to arrange for magnetic particles to attach to a variety of substances of interest.
  • the or each magnetic particle may be arranged so that it can only become attached to a single unit of a substance of interest, for example a single molecule. As such each particle may be provided with a single antibody or capture probe.
  • magnetic particles having different characteristics it is possible to distinguish between magnetic particles having different characteristics in a fluid.
  • magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances it is possible to determine the presence and/or concentration of more than one substance of interest in a given fluid.
  • Any suitable characteristic of the magnetic particles may be altered, including size, shape and magnetic susceptibility.
  • the chamber may have a volume of less than lO ⁇ L, preferably less than 5 ⁇ L.
  • the magnetic particles are mixed with the fluid by the application of an oscillating magnetic field to the chamber.
  • a sensitive detector of magnetic field such as a Hall Effect probe, is used to detect movement of magnetic particles throughout the fluid. As the probes and particles bind to the substances of interest the mass of particles will start to move together in the oscillating field creating a magnetic field pattern which will be distributed in a unique mode throughout the chamber. This can be detected by the magnetic field sensor and both its distribution and time-spatial development can be used to determine the concentration of the substance of interest in the fluid.
  • capture antibodies specific to the analyte of interest, are spatially immobilised at one part of the chamber and the magnetic particles are coated with a second antibody (tag probe) specific to the substance of interest.
  • tag probe a second antibody specific to the substance of interest.
  • the magnetic field due to the presence of bound particles increases at the location in the chamber of the capture antibodies and can be specifically measured at this site, thereby to infer the concentration of the substance of interest.
  • an applied magnetic field is used to specifically concentrate particles of different magnetic susceptibilities in the sample. This allows for the measurement of multiple substances, molecules or analytes in a sample, such as a blood sample, where each different type of magnetic particle carries a different capture probe.
  • Additional sensitivity may be gained by providing two chambers and sensing areas, one of which contains the fluid and particles, the other being a control chamber. By sensing the two chambers together and by taking a differential signal the system becomes immune to external magnetic influence as signals that affect both sensors together are effectively cancelled out.
  • Figure 1 is a schematic view of apparatus for performing an embodiment of the invention.
  • two types of iron oxide particles are provided, a first type of a first size and susceptibility and a second type of a second size and susceptibility. Both types of particles are coated with polystyrene to provide an inert surface to the particle. Subsequently the first type of particles are coated with a first antibody arranged to bond to a first substance of interest, and the second type of particles are coated with a second antibody arranged to bond to a second substance of interest.
  • Both types of particles are then introduced into a fluid in which it is desired to detect the presence and/or quantity of the first and second substances of interest. Over time and with agitation of the fluid the first type of particles will become attached to the first substance of interest and the second type of particles will be become attached to the second substance of interest. Sufficient quantities of each type of particle are introduced to ensure that a particle becomes bonded to each substance of interest.
  • The. fluid is subsequently analysed using the apparatus illustrated in figure 1.
  • the apparatus comprises two spaced apart rare earth permanent magnets 1, 5 having substantially parallel opposed flat facing surfaces 7 on one of which is mounted a shaped soft ion pole piece 2.
  • the pole piece is substantially triangular in cross- section presenting a wedge shaped profile extending away from its associated magnet 1, directed towards the other magnet 5.
  • the magnets 1, 5 and pole piece 2 are operative to generate a magnetic field gradient in the space between the two magnets.
  • the field gradient extends in the direction indicated as 3 in figure 1.
  • the magnet system further includes a linear array of Hall Effect devices 6 extending between the magnets in direction 3, or alternatively may include a single
  • Hall device moveable between the magnets along direction 3. in either case the Hall Effect devices or Hall Effect device operates to measure magnetic field strength between the magnets 1, 5 along direction 3.
  • the fluid to be analysed is introduced in a container, or in a living body, into a region of magnetic field gradient between two magnets 1, 5 and the resultant change in magnetic field, due to any of the above assays utilising magnetic particles, between the magnets along the direction 3 is measured by the Hall Effect device 3, or devices.
  • Pole pieces 2, 4 shape and control the magnetic field.
  • Apparatus suitable for analysing a fluid sample containing substances tagged with magnetic particles is also disclosed in WO 02/088696. If as described above, two types of particle, attached to respective substances of interest are utilised in this device, they will tend to migrate to two discrete points along the axis 3 where their presence will influence the measured magnetic field at that point. These points and the effect of the presence of particles on the magnetic field can be determined empirically. By calibration of the apparatus it is possible to determine the presence and/or concentration of the substances associated with each type of particle in the fluid sample. Of course any number of different types of particle may be employed in a single fluid to identify a corresponding number of substances of interest.
  • the particles can be utilised in a classic 'displacement assay' or 'flow displacement assay'.
  • the particles are immobilised on a surface.
  • the particles are able to bond to the substance of interest via their attachment to specific antibodies.
  • competition for the bonding site on the particle from the substance of interest results in the release of the particles into solution in an amount in proportion to the concentration of the substance of interest in the sample fluid.
  • the released particles are exposed to a field gradient as described above and accordingly, the particles become concentrated at a particular point along the field gradient according to their magnetic susceptibility. At this point, the field density is therefore increased.
  • the change in the field may be measured using a Hall Effect device or any other suitable magnetic sensor.
  • suitable calibration enables the determination of the presence and/or concentration of the substance(s) of interest in the sample.
  • one or more types of iron oxide particles of the type described above are provided in a chamber.
  • the chamber would typically have a volume of less than lO ⁇ L or in some embodiments 5 ⁇ L.
  • a fluid containing one or more substances of interest is then introduced to the chamber.
  • an oscillating magnetic field is applied to the chamber which has the effect of mixing the particles with the fluid.
  • the particle fluid mix can then be analysed as described in the first embodiment above to determine the presence and or concentration of the one or more substances of interest.
  • one or more types of iron oxide particles of the type described above are provided in a chamber.
  • the chamber would typically have a volume of less than lO ⁇ L or in some embodiments 5 ⁇ L.
  • a fluid containing one or more substances of interest is then introduced to the chamber.
  • an oscillating magnetic field is applied to the chamber which has the effect of mixing the particles with the fluid.
  • the magnetic filed pattern is detected by a suitable magnetic sensor, such as a Hall Effect device.
  • a suitable magnetic sensor such as a Hall Effect device.
  • the distribution and the time-spatial development of the pattern may be use to determine the presence and/or concentration of substances of interest in the fluid.
  • capture antibodies are immobilised at a specific location within the chamber, the capture antibodies specific to the substance of interest.
  • the magnetic particles are coated with a second antibody (tag probe) specific to the substance of interest.
  • the substance of interest binds to both the capture antibodies and the tag probe and accordingly, the magnetic particles become immobilised at the location of the capture antibodies.
  • a suitable magnetic field sensor such as a Hall Effect device, is then used to measure the magnetic field at this location.
  • the field strength can, through suitable calibration, be used to determine the presence and/or concentration of the substance of interest in a fluid.
  • an applied magnetic field can be use to specifically concentrate particles of particular susceptibilities at particular locations within the chamber. This allows for the determination of the presence and/or concentration of a plurality of different substances in a sample, provided each different type of magnetic particle carries a different capture probe.
  • two similar chambers may be used, one containing the fluid and the particles, the other being a control chamber.
  • the system is. not affected by external magnetic fields as these effect both chambers equally and are thus cancelled out.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Magnetic particles coated with specific antibodies for substances of interest are introduced into a fluid sample. Over time and with agitation, the magnetic particles become attached to the substance of interest within the fluid. The fluid is then introduced to a magnetic field gradient provided between two magnets (1, 5). the resultant change to the magnetic filed between the magnets (1, 5) is determine by a Hall Effect device (3) or a plurality of Hall Effect devices (3). This enables the presence and/or concentration of the substance of interest in the sample to be determined.

Description

METHOD OF DETERMINING THE PRESENCE AND/OR CONCENTRATION OF SUBSTANCES OF INTEREST IN FLUIDS
The present invention relates to a method of determining the presence and/or concentration of substances of interest in fluids, and particularly although not exclusively the presence and/or concentration of substances of interest in biological fluids including measurement in a living body, such as a human body.
In many medical, biological, manufacturing and other systems there is a requirement to determine the presence and/or concentration of various substances in fluids, including, but not limited to molecules such as proteins, hormones or DNA. In the normal course of analysis immunoassay systems are employed to measure such molecules. These immunoassays rely on the presence of a tagged antibody or probe (ligand) which adheres to or binds to a molecule of interest. The presence of the tagged probe is detected and the quantity of probe detected related to the concentration of the molecule under analysis. Multiple probe systems with a capture probe or antibody and a second tagged probe or antibody to reveal the captured molecule are common. Probes have been used with tags that are radioactive, enzymatic, fluorescent, chemiluminescent and spectrophotmetric or colourimetric. End points of tagged probe measurement can therefore be revealed in a variety of systems include spectrophotometric, electrochemical, radioactive, colourimetric, amperometric or potentiometric. Magnetic beads have been employed in multiple probe systems as a solid phase for the capture probe, providing a highly mobile bead system with high surface area for capture probe attachment [1]. Secondary probes or antibodies can then be added after molecular attachment to the capture probe and in the commonest application a magnetic field is then used to draw together the beads allowing a concentrate to form where the level of the tag can be measured. This can be read directly, if, for example, the tag is fluorescent or can be read by an indirect method whereby a solution is introduced to react with the probe tag producing a measurable effect (such as the production of light by chemiluminescent reactions with the tag). A number of documents, US 6,046,585, US 6,275,031, US 6,437,563 & US 6,
483,303, (all assigned to Quantum Dynamics Inc) all disclose using an immunoassay to determine the presence of magnetic particles complexed with substances of interest in a sample. A magnetic field is applied to the sample and the magnetic particles are thereby caused to oscillate at the excitation frequency in the manner of a dipole to create their own fields. The fields are inductively coupled to at least one sensor to produce a useful indication of the presence of said magnetic particles.
It is an object of the present invention to provide an alternative method of determining the presence and/or concentration of substances of interest in a fluid. It is an object of embodiments of the present invention to enable determination of the presence and/or concentration of substances in low volumes of fluid, typically less than 5μL. It is a preferred outcome of the invention that such assays should take place under rapid capillary and / or turbulent flow conditions to reduce assay times. According to an aspect of the present invention there is provided a method of determining the presence and/or concentration of one or more substances of interest in a fluid, the method comprising the steps of: attaching a magnetic particle to the or each substance of interest in the fluid and introducing the fluid into an inhomogeneous magnetic field having a field gradient and thereby determining the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest.
Hitherto determination of the presence and/or concentration of magnetic particles in this manner has not been employed to infer the presence of substances of interest attached to those particles. Employing this technique enables rapid analysis of a fluid, and effective analysis of very small volumes of fluid.
The fluid may be a liquid or gas, and may be a biological fluid such as a body fluid.
Substances of interest may include naturally occurring substances, substances that are the result of a chemical or biological reaction, such as drug by-products, and substances introduced into a fluid sample. The substance may be a compound, especially a molecule and could be, for example a protein, hormone or DNA section.
By "magnetic" particles is to be understood particles of non-zero magnetic susceptibility. The or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. A homogeneous or heterogeneous mixture of such particles may be employed. In one embodiment the or each particle is formed from iron oxide. Particles of size in the range 5 nanometers to 100 micrometers may be used or in some embodiments particles of size in the range 5 nanometers to 50 micrometers may be used.
The or each particle may be attached to a substance of interest by means of a further substance, which shall be referred to as a bonding substance. The or each particle may be coated with the bonding substance. The bonding substance may be a protein, and in some embodiments it is an antibody or probe (ligand).
The or each magnetic particle may be coated with a material to facilitate adherence of a bonding substance to the particle. A suitable coating material is polystyrene.
Magnetic particles may be attached to substances of interest prior to their introduction into a fluid, for example in the case of a drug injected into a human body. Alternatively magnetic particles coated with an appropriate bonding substance may be introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest, for example appropriately coated magnetic particles could be injected into a human body in order to identify the presence and/or concentration of specific drug by-products.
By appropriate selection of the bonding substance it is possible to arrange for magnetic particles to attach to a variety of substances of interest. The or each magnetic particle may be arranged so that it can only become attached to a single unit of a substance of interest, for example a single molecule. As such each particle may be provided with a single antibody or capture probe.
It is possible to distinguish between magnetic particles having different characteristics in a fluid. By using magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances it is possible to determine the presence and/or concentration of more than one substance of interest in a given fluid. Any suitable characteristic of the magnetic particles may be altered, including size, shape and magnetic susceptibility. In some instances it is also possible to distinguish between magnetic particles with the same or similar characteristics attached to different substances of interest in a fluid, by virtue of differing characteristics of the substance of interest such as a mass.
In one embodiment the effect of the fluid to be analysed on the magnetic field is measured using a magnetic field sensor to determine magnetic particles in the fluid, and thereby the presence and/or concentration of substances of interest. Preferably the magnetic field gradient is along a line in space. When magnetic particles in a fluid are introduced into the field gradient they will experience a force. The force experienced by each particle will depend upon its characteristics. Where a fluid containing a number of magnetic particles which respond differently to a magnetic field is placed into an inhomogeneous magnetic field the different particles are subject to different forces and will thus tend to migrate to different regions of the field. The magnetic particles present in the fluid will also influence the magnetic field in different ways. With knowledge of the way in which different particles introduced into a fluid influence magnetic field it is possible to infer their presence and also the concentration of the particles in the fluid. In one embodiment particles of differing susceptibility are present in a fluid and the fluid is introduced into a magnetic field gradient. Particles of the same susceptibility will tend to migrate to the same position within the field gradient. The amount of particles present at any one point will affect the field strength at that point. By measuring the strength of magnetic field in the region of the fluid along the field gradient it is possible to determine the presence and quantity of magnetic particles of differing susceptibility and thereby the concentration of particles of the same or similar susceptibility in the fluid sample.
Field gradients in the range 50 to 200 Tesla per metre may be typically employed and not excluding other field gradients. Permanent magnets having shaped pole pieces may typically be used to provide a magnetic field gradient. In yet another embodiment the particles can be detected in a classic
'displacement assay' or 'flow displacement assay'. Here the particles are immobilised on a surface but are able to bond to a substance of interest though a specific bonding substance such as an antibody. A sample is introduced to this surface which contains the substance of interest in an unknown quantity. Competition for the binding site on the particle from the substance of interest in the sample will release the magnetic particles into solution in proportion to the concentration of the substance of interest in the sample. In the present invention, the released particles experience a magnetic field gradient and hence are concentrated at a point determined by their susceptibility. This concentration varies the magnetic field and creates a point of high field density. A magnetic sensor is placed at the point of highest field density to detect the particles thus greatly increasing the sensitivity of measurement. The sensor may be a Hall Sensor, or any other sensitive magnetic measurement sensor. The immobilised particles can be bound via any suitable bonding substance to substances of interest, multiple layers of different bonding substances can be used to create suitable sites for competition from substances of interest in the sample.
Advantageously there is no requirement for a secondary antibody capture site to "collect" the particles together for sensing. This makes the disposable element simpler and cheaper. Additionally, there is no requirement for complex alignment systems between sensor and disposable to give accuracy and consistency. The magnetic field gradient automatically concentrates all freed particles in the sensing area. Furthermore, the use of NdFeb (Neodymium Iron Boron) permanent magnets together with correctly designed pole pieces allows very high field densities to be created. This gives much greater sensitivity with no power input which is essential for small, low cost point of care systems
In the prior art, a displacement assay is used in the analytical system but measurement is made by a complex oscillating coil system, and an antibody capture site for particles. This cannot create the same level of field density, even with very high power inputs, and hence sensitivity is compromised. This results in more complex manufacture for both the sensing system and the disposable test element. Therefore it is not suitable for small, point of care machines.
Furthermore prior art methods using magnetic particles utilise an immunoassay and adjacent magnets to move and measure spatial separation of magnetic particles the present invention utilises the properties of a magnetic field gradient, knowledge of the effect of the particles on total field and a sensitive magnetic sensor to be able to determine the particle flow, both spatially and temporally, during the assay and to thereby determine the quantity of the substance of interest present in the sample being examined. It should be understood that the ability to understand and utilise magnetic field gradients with magnetic particles in the present invention may also be employed to maximise the immunoassay efficiency and performance. In this manner the present invention may utilise oscillating and other magnetic field arrangements to enhance particle - sample interactions and/or to manipulate flow rates during assays through manipulation of the particles. For example, a magnetic field may be introduced that will directly cause the magnetic particles to coagulate or cluster within a device slowing flow rates in the sample. Higher amplification may be used to achieve greater sensitivity. Furthermore, the method may include the application of an oscillating magnetic field to a solution of the fluid to be analysed and the magnetic particles to ensure mixing before introducing the fluid into the said inhomogeneous field with a field gradient. According to another aspect of the present invention there is provided a method of determining the presence and/or concentration of one or more substances of interest in a fluid, the method comprising the steps of: introducing a fluid to be analysed is into a chamber containing magnetic particles bound with probes specific for the capture of the molecule of interest; mixing the magnetic particles with the fluid by the application of an oscillating magnetic field to the chamber to thereby determine the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest.
The fluid may be a liquid or gas, and may be a biological fluid such as a body fluid.
Substances of interest may include naturally occurring substances, substances that are the result of a chemical or biological reaction, such as drug by-products, and substances introduced into a fluid sample. The substance may be a compound, especially a molecule and could be, for example a protein, hormone or DNA section. By "magnetic" particles is to be understood particles of non-zero magnetic susceptibility. The or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. A homogeneous or heterogeneous mixture of such particles may be employed. In one embodiment the or each particle is formed from iron oxide. Particles of size in the range 5 nanometers to 100 micrometers may be used or in some embodiments particles of size in the range 5 nanometers to 50
micrometers may be used. The or each particle may be attached to a substance of interest by means of a further substance, which shall be referred to as a bonding substance. The or each particle may be coated with the bonding substance. The bonding substance may be a protein, and in some embodiments it is an antibody or probe (ligand). The or each magnetic particle may be coated with a material to facilitate adherence of a bonding substance to the particle. A suitable coating material is polystyrene.
Magnetic particles may be attached to substances of interest prior to their introduction into a fluid, for example in the case of a drug injected into a human body. Alternatively magnetic particles coated with an appropriate bonding substance may be introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest, for example appropriately coated magnetic particles could be injected into a human body in order to identify the presence and/or concentration of specific drug by-products. By appropriate selection of the bonding substance it is possible to arrange for magnetic particles to attach to a variety of substances of interest. The or each magnetic particle may be arranged so that it can only become attached to a single unit of a substance of interest, for example a single molecule. As such each particle may be provided with a single antibody or capture probe. It is possible to distinguish between magnetic particles having different characteristics in a fluid. By using magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances it is possible to determine the presence and/or concentration of more than one substance of interest in a given fluid. Any suitable characteristic of the magnetic particles may be altered, including size, shape and magnetic susceptibility.
In some instances it is also possible to distinguish between magnetic particles with the same or similar characteristics attached to different substances of interest in a fluid, by virtue of differing characteristics of the substance of interest such as a mass.
The chamber may have a volume of less than lOμL, preferably less than 5μL. The magnetic particles are mixed with the fluid by the application of an oscillating magnetic field to the chamber. A sensitive detector of magnetic field, such as a Hall Effect probe, is used to detect movement of magnetic particles throughout the fluid. As the probes and particles bind to the substances of interest the mass of particles will start to move together in the oscillating field creating a magnetic field pattern which will be distributed in a unique mode throughout the chamber. This can be detected by the magnetic field sensor and both its distribution and time-spatial development can be used to determine the concentration of the substance of interest in the fluid.
In a variation to this embodiment capture antibodies, specific to the analyte of interest, are spatially immobilised at one part of the chamber and the magnetic particles are coated with a second antibody (tag probe) specific to the substance of interest. As the molecule binds to the capture and tag antibodies, the magnetic field due to the presence of bound particles increases at the location in the chamber of the capture antibodies and can be specifically measured at this site, thereby to infer the concentration of the substance of interest. In a further variation an applied magnetic field is used to specifically concentrate particles of different magnetic susceptibilities in the sample. This allows for the measurement of multiple substances, molecules or analytes in a sample, such as a blood sample, where each different type of magnetic particle carries a different capture probe.
Additional sensitivity may be gained by providing two chambers and sensing areas, one of which contains the fluid and particles, the other being a control chamber. By sensing the two chambers together and by taking a differential signal the system becomes immune to external magnetic influence as signals that affect both sensors together are effectively cancelled out.
In order that the invention may be more clearly understood embodiments thereof will now be described by way of example with reference to the accompanying drawings of which:
Figure 1 is a schematic view of apparatus for performing an embodiment of the invention.
In one embodiment of the present invention two types of iron oxide particles are provided, a first type of a first size and susceptibility and a second type of a second size and susceptibility. Both types of particles are coated with polystyrene to provide an inert surface to the particle. Subsequently the first type of particles are coated with a first antibody arranged to bond to a first substance of interest, and the second type of particles are coated with a second antibody arranged to bond to a second substance of interest.
Both types of particles are then introduced into a fluid in which it is desired to detect the presence and/or quantity of the first and second substances of interest. Over time and with agitation of the fluid the first type of particles will become attached to the first substance of interest and the second type of particles will be become attached to the second substance of interest. Sufficient quantities of each type of particle are introduced to ensure that a particle becomes bonded to each substance of interest.
The. fluid is subsequently analysed using the apparatus illustrated in figure 1. The apparatus comprises two spaced apart rare earth permanent magnets 1, 5 having substantially parallel opposed flat facing surfaces 7 on one of which is mounted a shaped soft ion pole piece 2. The pole piece is substantially triangular in cross- section presenting a wedge shaped profile extending away from its associated magnet 1, directed towards the other magnet 5. The magnets 1, 5 and pole piece 2 are operative to generate a magnetic field gradient in the space between the two magnets. The field gradient extends in the direction indicated as 3 in figure 1.
The magnet system further includes a linear array of Hall Effect devices 6 extending between the magnets in direction 3, or alternatively may include a single
Hall device moveable between the magnets along direction 3. in either case the Hall Effect devices or Hall Effect device operates to measure magnetic field strength between the magnets 1, 5 along direction 3.
The fluid to be analysed is introduced in a container, or in a living body, into a region of magnetic field gradient between two magnets 1, 5 and the resultant change in magnetic field, due to any of the above assays utilising magnetic particles, between the magnets along the direction 3 is measured by the Hall Effect device 3, or devices.
Pole pieces 2, 4 shape and control the magnetic field.
Apparatus suitable for analysing a fluid sample containing substances tagged with magnetic particles is also disclosed in WO 02/088696. If as described above, two types of particle, attached to respective substances of interest are utilised in this device, they will tend to migrate to two discrete points along the axis 3 where their presence will influence the measured magnetic field at that point. These points and the effect of the presence of particles on the magnetic field can be determined empirically. By calibration of the apparatus it is possible to determine the presence and/or concentration of the substances associated with each type of particle in the fluid sample. Of course any number of different types of particle may be employed in a single fluid to identify a corresponding number of substances of interest.
In a variation of this embodiment, the particles can be utilised in a classic 'displacement assay' or 'flow displacement assay'. In such embodiments, the particles are immobilised on a surface. As previously, the particles are able to bond to the substance of interest via their attachment to specific antibodies. When a sample fluid is introduced on to the surface, competition for the bonding site on the particle from the substance of interest results in the release of the particles into solution in an amount in proportion to the concentration of the substance of interest in the sample fluid. The released particles are exposed to a field gradient as described above and accordingly, the particles become concentrated at a particular point along the field gradient according to their magnetic susceptibility. At this point, the field density is therefore increased. The change in the field may be measured using a Hall Effect device or any other suitable magnetic sensor. As above, suitable calibration enables the determination of the presence and/or concentration of the substance(s) of interest in the sample.
In an alternative embodiment, one or more types of iron oxide particles of the type described above are provided in a chamber. The chamber would typically have a volume of less than lOμL or in some embodiments 5μL. A fluid containing one or more substances of interest is then introduced to the chamber. After the introduction of the fluid to the chamber, an oscillating magnetic field is applied to the chamber which has the effect of mixing the particles with the fluid. The particle fluid mix can then be analysed as described in the first embodiment above to determine the presence and or concentration of the one or more substances of interest. In a further alternative embodiment, one or more types of iron oxide particles of the type described above are provided in a chamber. The chamber would typically have a volume of less than lOμL or in some embodiments 5μL. A fluid containing one or more substances of interest is then introduced to the chamber. After the introduction of the fluid to the chamber, an oscillating magnetic field is applied to the chamber which has the effect of mixing the particles with the fluid. Continued application of the oscillating magnetic field causes the mass of particles to move together in the oscillating field creating a magnetic filed pattern distributed in a unique mode throughout the chamber. The magnetic filed pattern is detected by a suitable magnetic sensor, such as a Hall Effect device. With suitable calibration, the distribution and the time-spatial development of the pattern may be use to determine the presence and/or concentration of substances of interest in the fluid. In a variation of the above embodiments, capture antibodies are immobilised at a specific location within the chamber, the capture antibodies specific to the substance of interest. The magnetic particles are coated with a second antibody (tag probe) specific to the substance of interest. The substance of interest binds to both the capture antibodies and the tag probe and accordingly, the magnetic particles become immobilised at the location of the capture antibodies. A suitable magnetic field sensor, such as a Hall Effect device, is then used to measure the magnetic field at this location. The field strength can, through suitable calibration, be used to determine the presence and/or concentration of the substance of interest in a fluid. Alternatively, rather than immobilised capture antibodies, an applied magnetic field can be use to specifically concentrate particles of particular susceptibilities at particular locations within the chamber. This allows for the determination of the presence and/or concentration of a plurality of different substances in a sample, provided each different type of magnetic particle carries a different capture probe.
In a further variation of the above embodiments, to gain additional sensitivity, two similar chambers may be used, one containing the fluid and the particles, the other being a control chamber. By sensing the two chambers together and taking a differential signal, the system is. not affected by external magnetic fields as these effect both chambers equally and are thus cancelled out.
The above embodiments are described by way of example only, many variations are possible without departing from the present invention.
References
1. Application of magnetic techniques in the field of drug discovery and biomedicine ZM Saiye, SD Telang and CN Ramchand, BioMagnetic Research and Technology Volume 1

Claims

Claims
1. A method of determining the presence and/or concentration of one or more substances of interest in a fluid, the method comprising the steps of: attaching a magnetic particle to the or each substance of interest in the fluid and introducing the fluid into an inhomogeneous magnetic field having a field gradient and thereby determining the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest. 2. A method as claimed in claim 1 wherein the fluid is a liquid. 3. A method as claimed in claim 2 wherein the fluid is a biological fluid such as a body fluid. 4. A method as claimed in claim 1 wherein the fluid is a gas. 5. A method as claimed in any preceding claim wherein the substance is a compound. 6. A method as claimed in any preceding claim wherein the substance is any one of a protein, a hormone or a DNA section. 7. A method as claimed in any preceding claim wherein the or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. 8. A method as claimed in any preceding claim wherein there is a homogeneous or a heterogeneous mixture of magnetic particles may be employed.
. A method as claimed in any preceding claim wherein the or each magnetic particle is formed from iron oxide.
10. A method as claimed in any preceding claim wherein the magnetic particles range in size from 5 nanometers to 100 micrometers. 11. A method as claimed in any preceding claim wherein the or each magnetic particle is attached to a substance of interest by means of a further bonding substance. 12. A method as claimed in claim 11 wherein the or each magnetic particle is coated with the bonding substance. 13. A method as claimed in claim 11 or claim 12 wherein the bonding substance is any one of a protein an antibody or a probe (ligand). 14. A method as claimed in any one of claims 11 to 13 wherein the or each magnetic particle is coated with a material to facilitate adherence of the bonding substance to the particle. 15. A method as claimed in claim 14 wherein the material is polystyrene.
16. A method as claimed in any preceding claim wherein magnetic particles are attached to substances of interest prior to their introduction into a fluid.
17. A method as claimed in any one of claims 11 to 16 wherein magnetic particles coated with an appropriate bonding substance are introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest.
18. A method as claimed in any one of claims 11 to 17 wherein the bonding substance is selected to arrange for magnetic particles to attach to a variety of substances of interest.
19. A method as claimed in any preceding claim wherein the or each magnetic particle is arranged so that it can only become attached to a single unit of a substance of interest.
20. A method as claimed in any preceding claim wherein the or each particle is provided with a single antibody or capture probe.
21. A method as claimed in any preceding claim wherein magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances are used to determine the presence and/or concentration of more than one substance of interest in a given fluid.
22. A method as claimed in claim 21 wherein any one of size, shape and magnetic susceptibility of the magnetic particles are altered.
23. A method as claimed in any preceding claim wherein differing characteristics of the substance of interest are used to distinguish between magnetic particles with the same or similar characteristics attached to different substances of interest. 24. A method as claimed in any preceding claim wherein the effect of the fluid to be analysed on the magnetic field is measured using a magnetic field sensor to determine magnetic particles in the fluid, and thereby the presence and/or concentration of substances of interest.
25. A method as claimed in any preceding claim wherein the a magnetic field gradient is along a line in space.
26. A method as claimed in any preceding claim wherein particles of differing susceptibility are present in a fluid. 27. A method as claimed in claim 26 wherein by measuring tine strength of magnetic field in the region of the fluid along the field gradient the presence and quantity of magnetic particles of differing susceptibility and thereby the concentration of particles of the same or similar susceptibility in the fluid sample is determined. 28. A method as claimed in any preceding claim wherein field gradients in the range 50 to 200 Tesla per metre are employed. 29. A method as claimed in claim any preceding claim wherein permanent magnets having shaped pole pieces are used to provide the magnetic field gradient. 30. A method as claimed in any preceding claim wherein the particles are detected in a classic 'displacement assay' or 'flow displacement assay'. 31. A method as claimed in claim 30 wherein the magnetic particles are immobilised on a surface bound to a substance of interest though a specific bonding substance such as an antibody. 32. A method as claimed in claim 30 or claim 31 wherein the released particles enter a magnetic field gradient and are concentrated at a particular point in the gradient determined by their susceptibility.
33. A method as claimed in claim 32 wherein a magnetic sensor is placed at the point of highest field density.
34. A method as claimed in any preceding claim wherein the sensor is a Hall Sensor. 35. A method as claimed in any one of claims 30 to 34 wherein the immobilised particles are bound via a bonding substance to substances of interest. 36. A method as claimed in any one of claims 30 to 35 wherein multiple layers of different bonding substances are used to create suitable sites for competition from substances of interest in the sample. 37. A method as claimed in any one of claims 30 to 36 wherein an oscillating magnetic field arrangement is applied to enhance particle - sample interactions and/or to manipulate flow rates.
38. A method as claimed in any one of claims 30 to 37 wherein a field is introduced that will directly cause the magnetic particles to coagulate or cluster within a device, slowing flow rates in the sample.
39. A method as claimed in any preceding claim wherein an oscillating magnetic field is applied to a solution of the fluid to be analysed and the magnetic particles to ensure mixing before introducing the fluid into the said inhomogeneous field with a field gradient. 40. A method of determining the presence and/or concentration of one or more substances of interest in a fluid, the method comprising the steps of: introducing a fluid to be analysed into a chamber containing magnetic particles bound with probes specific for the capture of the molecule of interest; mixing the magnetic particles with the fluid by the application of an oscillating magnetic field to the chamber to thereby determine the presence and/or concentration of magnetic particles in the fluid thereby to determine the presence and/or concentration of the one or more substances of interest. 41. A method as claimed in claim 40 wherein the fluid is a liquid.
42. A method as claimed in claim 41 wherein the fluid is a biological fluid such as a body fluid.
43. A method as claimed in claim 40 wherein the fluid is a gas.
44. A method as claimed in claim 40 wherein the substance is a compound. 45. A method as claimed in claim 44 wherein the substance is any one of a protein, a hormone or a DNA section. 46. A method as claimed in any one of claims 40 to 45 wherein the or each magnetic particle may be ferromagnetic, diamagnetic, paramagnetic or superparamagnetic. 47. A method as claimed in any one of claims 40 to 46 wherein there is a homogeneous or a heterogeneous mixture of such particles may be employed.
48. A method as claimed in any one of claims 40 to 47 wherein the or each magnetic particle is formed from iron oxide.
49. A method as claimed in any one of claims 40 to 48 wherein the magnetic particles range in size from 5 nanometers to 50 micrometers.
50. A method as claimed in any one of claims 40 to 49 wherein the or each magnetic particle is attached to a substance of interest by means of a further bonding substance.
51. A method as claimed in any one of claims 40 to 50 wherein the particle is coated with the bonding substance.
52. A method as claimed in claim 51 wherein the bonding substance is any one of a protein an antibody or a probe (ligand). 53. A method as claimed in claim 51 or claim 52 wherein the or each magnetic particle is coated with a material to facilitate adherence of the bonding substance to the particle.
54. A method as claimed in claim 53 wherein the material is polystyrene.
55. A method as claimed in any one of claims 40 to 54 wherein magnetic particles are attached to substances of interest prior to their introduction into a fluid.
56. A method as claimed in any one of claims 40 to 55 wherein magnetic particles coated with an appropriate bonding substance are introduced into a fluid containing a substance of interest so that they will become attached to the substance of interest. 57. A method as claimed in any one of claims 51 to 56 wherein the bonding substance is selected to arrange for magnetic particles to attach to a variety of substances of interest.
58. A method as claimed in any one of claims 40 to 57 wherein the or each magnetic particle is arranged so that it can only become attached to a single unit of a sub stance of interest.
59. A method as claimed in any one of claims 40 to 58 wherein the or each magnetic particle is provided with a single antibody or capture probe.
60. A method as claimed in any one of claims 40 to 59 wherein magnetic particles having common known characteristics attached to a first bonding substance and further magnetic particles having different known characteristics attached to other bonding substances are used to determine the presence and/or concentration of more than one substance of interest in a given fluid.
61. A method as claimed in claim 60 wherein any one of size, shape and magnetic susceptibility of the magnetic particles are altered.
62. A method as claimed in any one of claims 40 to 61 wherein differing characteristics of the substance of interest are used to distinguish between magnetic particles with the same or similar characteristics attached to different substances of interest.
63. A method as claimed in any one of claims 40 to 62 wherein the effect of the fluid to be analysed on the magnetic field is measured using a magnetic field sensor to determine magnetic particles in the fluid, and thereby the presence and/or concentration of substances of interest.
64. A method as claimed in any one of claims 40 to 63 wherein the chamber has a volume of less than lOμL.
65. A method as claimed in any one of claims 40 to 63 wherein the chamber has a volume of less than 5μL 66. A method as claimed in any one of claims 40 to 65 wherein a Hall effect probe is used to detect movement of magnetic particles throughout the fluid. 67. A method as claimed in any one of claims 40 to 66 wherein as the probes and particles bind to the substances of interest, the mass of particles will start to move together in the oscillating field creating a magnetic field pattern which will be distributed in a unique mode throughout the chamber.
68. A method as claimed in claim 67 wherein the distribution and/or the time- spatial development of the pattern is used to determine the concentration of the substance of interest in the fluid.
69. A method as claimed in any one of claims 40 to 68 wherein capture antibodies, specific to the analyte of interest, are spatially immobilised at one part of the chamber and the magnetic particles are coated with a second antibody (tag probe) specific to the substance of interest. 70. A method as claimed in claim 69 wherein as the substance of interest binds to the capture and tag antibodies, the magnetic field due to the presence of bound particles increases at the location in the chamber of the capture antibodies.
71. A method as claimed in claim 69 or claim 70 wherein the magnetic field is specifically measured at the location in the chamber of the capture antibodies to infer the concentration of the substance of interest.
72. A method as claimed in any one of claims 40 to 71 wherein an applied magnetic field is used to specifically concentrate particles of different magnetic susceptibilities in the sample.
73. A method as claimed in any one of claims 40 to 72 wherein two chambers and sensing areas are provided, one of which contains the fluid and particles, the other being a control chamber.
EP05758809A 2004-06-19 2005-06-20 Method of determining the presence and/or concentration of substances of interest in fluids Withdrawn EP1766399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413752.7A GB0413752D0 (en) 2004-06-19 2004-06-19 Method of determining the presence and/or concentration of substances of interest in fluids
PCT/GB2005/002427 WO2005124345A2 (en) 2004-06-19 2005-06-20 Method of determining the presence and/or concentration of substances of interest in fluids

Publications (1)

Publication Number Publication Date
EP1766399A2 true EP1766399A2 (en) 2007-03-28

Family

ID=32750223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05758809A Withdrawn EP1766399A2 (en) 2004-06-19 2005-06-20 Method of determining the presence and/or concentration of substances of interest in fluids

Country Status (6)

Country Link
US (1) US20070224604A1 (en)
EP (1) EP1766399A2 (en)
JP (1) JP2008503714A (en)
CN (1) CN101027558A (en)
GB (1) GB0413752D0 (en)
WO (1) WO2005124345A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166730A1 (en) * 2006-01-19 2007-07-19 Menon & Associates, Inc. Magnetic resonance system and method to detect and confirm analytes
JP5438506B2 (en) * 2006-05-10 2014-03-12 コーニンクレッカ フィリップス エヌ ヴェ Magnetic system
GB0615738D0 (en) * 2006-08-08 2006-09-20 Ivmd Uk Ltd Method of determining the presence of substance if interest in fluids
EP2034324A3 (en) * 2007-07-20 2010-06-16 Koninklijke Philips Electronics N.V. Sensor cartridge
CN101971015A (en) * 2008-01-17 2011-02-09 加利福尼亚大学董事会 Integrated magnetic field generation and detection platform
US9958442B2 (en) 2009-02-11 2018-05-01 Duke University Sensors incorporating antibodies and methods of making and using the same
WO2011021142A1 (en) * 2009-08-19 2011-02-24 Koninklijke Philips Electronics N.V. Detection of different target components by cluster formation
GB201006203D0 (en) 2010-04-14 2010-06-02 Bio Amd Holdings Ltd Immunoassay apparatus incorporating microfluidic channel
US10571464B2 (en) * 2012-10-11 2020-02-25 Orgentec Diagnostika Gmbh Detecting an analyte and determining the concentration of an analyte using magnetizable beads
US10407716B2 (en) 2014-03-13 2019-09-10 Duke University Electronic platform for sensing and control of electrochemical reactions
US10337967B2 (en) * 2016-01-08 2019-07-02 Salus Discovery Llc Magnetic base for collection and release of paramagnetic particles
CN105713898B (en) * 2016-02-22 2019-06-18 张学文 Super quick micro target substance automatically extracts/detection method
KR102630604B1 (en) 2017-09-25 2024-01-30 키아겐 게엠베하 Device and method for immobilizing biomolecules using magnetic particles
CN107807142A (en) * 2017-10-26 2018-03-16 北京航空航天大学 A kind of measuring system and measuring method of solid impurities concentration
US11609208B2 (en) 2019-04-12 2023-03-21 Western Digital Technologies, Inc. Devices and methods for molecule detection based on thermal stabilities of magnetic nanoparticles
US11112468B2 (en) 2019-04-12 2021-09-07 Western Digital Technologies, Inc. Magnetoresistive sensor array for molecule detection and related detection schemes
US11327073B2 (en) 2019-04-12 2022-05-10 Western Digital Technologies, Inc. Thermal sensor array for molecule detection and related detection schemes
US11738336B2 (en) 2019-04-12 2023-08-29 Western Digital Technologies, Inc. Spin torque oscillator (STO) sensors used in nucleic acid sequencing arrays and detection schemes for nucleic acid sequencing
WO2020210370A1 (en) 2019-04-12 2020-10-15 Roche Sequencing Solutions, Inc. Nucleic acid sequencing by synthesis using magnetic sensor arrays
US11579217B2 (en) 2019-04-12 2023-02-14 Western Digital Technologies, Inc. Devices and methods for frequency- and phase-based detection of magnetically-labeled molecules using spin torque oscillator (STO) sensors
US11208682B2 (en) 2019-09-13 2021-12-28 Western Digital Technologies, Inc. Enhanced optical detection for nucleic acid sequencing using thermally-dependent fluorophore tags
US11747329B2 (en) * 2019-11-22 2023-09-05 Western Digital Technologies, Inc. Magnetic gradient concentrator/reluctance detector for molecule detection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2647931B2 (en) * 1988-10-31 1997-08-27 オリンパス光学工業株式会社 Immunological measurement method
JP2884604B2 (en) * 1989-07-19 1999-04-19 東ソー株式会社 Automatic immunoassay device and method of using the same
CA2104800A1 (en) * 1992-10-08 1994-04-09 Saleh M. Faruque Non-interfering frequency plan for cellular communication systems
AU689768B2 (en) * 1993-02-17 1998-04-09 Cardiovascular Diagnostics, Inc. Dry chemistry cascade immunoassay and affinity assay
US5841023A (en) * 1993-08-31 1998-11-24 Boehringer Mannheim Corporation Magnet for medical instrument
US5807758A (en) * 1995-07-21 1998-09-15 Lee; Gil U. Chemical and biological sensor using an ultra-sensitive force transducer
US5958706A (en) * 1996-03-27 1999-09-28 Tdk Corporation Fine magnetic particles containing useful proteins bound thereto, process for producing the same, and use thereof
DE19616467A1 (en) * 1996-04-25 1997-11-06 Johannes Christian Koziol Non-invasive blood analysis method
EP0872736A1 (en) * 1997-04-18 1998-10-21 Byk Gulden Italia S.p.A. Assay utilizing magnetic particles
US6437563B1 (en) * 1997-11-21 2002-08-20 Quantum Design, Inc. Method and apparatus for making measurements of accumulations of magnetically susceptible particles combined with analytes
US6136271A (en) * 1998-02-23 2000-10-24 International Technidyne Corporation Solid state apparatus employing hall effect sensors for detecting the coagulation of blood
WO2001096857A2 (en) * 2000-06-14 2001-12-20 Board Of Regents, The University Of Texas System Method and apparatus for combined magnetophoretic and dielectrophoretic manipulation of analyte mixtures
GB0106250D0 (en) * 2001-03-13 2001-05-02 Hall Effect Technologies Ltd Apparatus and method for analysing blood
JP2002357594A (en) * 2001-03-28 2002-12-13 Olympus Optical Co Ltd Device and method for identifying magnetic particles
GB0110313D0 (en) * 2001-04-27 2001-06-20 Hall Effect Technologies Ltd Apparatus and method for analysing a fluid
US7232691B2 (en) * 2001-11-27 2007-06-19 Los Alamos National Security, Llc Bioassay and biomolecular identification, sorting, and collection methods using magnetic microspheres
AU2002348754A1 (en) * 2001-12-21 2003-07-09 Koninklijke Philips Electronics N.V. Magnetoresistive sensing device, system and method for determining a density of magnetic particles in fluid
US7126331B2 (en) * 2002-07-29 2006-10-24 The United States Of America As Represented By The Secretary Of The Navy Integrated gradiometer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005124345A2 *

Also Published As

Publication number Publication date
CN101027558A (en) 2007-08-29
WO2005124345A2 (en) 2005-12-29
JP2008503714A (en) 2008-02-07
US20070224604A1 (en) 2007-09-27
WO2005124345A3 (en) 2006-04-20
GB0413752D0 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
AU2023241336B2 (en) Superparamagnetic particle imaging and its applications in quantitative multiplex stationary phase diagnostic assays
US20070224604A1 (en) Method of Determining the Presence and/or Concentration of Substances of Interest in Fluids
RU2505816C2 (en) Cartridge for analyses with magnetic particles
US20080206104A1 (en) Accurate Magnetic Biosensor
EP2558204B1 (en) Assay apparatus incorporating a microfluidic channel and assay method
EP2078199B1 (en) Magnetic and/or electric label assisted detection system and method
JP2008544246A5 (en)
HU225636B1 (en) Method for detecting analyte(s) in fluid
WO2009083856A2 (en) Concentrated unbound magnetic particle assay for biosensors
EP3295163B1 (en) Devices and methods for increasing magnetic sensor sensitivity
US20080206892A1 (en) Rapid Magnetic Biosensor With Integrated Arrival Time Measuremnt
CN101438162A (en) Accurate magnetic biosensor
EP1936350A1 (en) A method for quantitatively measuring agglutination parameters
Wu et al. Magnetic Nanoparticle-Based Biosensing
WO2008017829A1 (en) Method of determining the presence of substances of interest in fluids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080623

19U Interruption of proceedings before grant

Effective date: 20080926

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20210601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

32PN Public notification

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 2524 DATED 28/04/2022)

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211202